Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.Follow Magenta on Twitter: @magentatx.

OrbiMed

Janus Henderson Investors

Deep Track Capital

Great Point Partners

TCG Crossover

EcoR1 Capital

The Watermill Group

Access Industries

Be The Match BioTherapies

Casdin Capital

Magenta Therapeutics

Gamida Cell Ltd is a clinical-stage biotechnology company focused on developing cell therapies for the treatment of cancer and rare genetic diseases.

Gamida Cell Ltd

Bluebird Bio Inc is a biotechnology company that develops gene therapies for severe genetic diseases and cancer.

Bluebird Bio Inc

Novartis AG is a multinational pharmaceutical company engaged in the research, development, manufacturing, and marketing of a range of healthcare products.

Novartis AG

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing next-generation antibody complement therapeutics.

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Magenta Therapeutics, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 4, 2024 11:55 PM	841ddb77
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 4, 2024 11:55 PM	26137d9f
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 4, 2024 11:55 PM	4065a8cb
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 4, 2024 11:55 PM	06ee5dc3
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:MAGENTATX

Dianthus Therapeutics, Inc.

Last Close

0.76

11/09 20:00

Market Cap

42.44M

Beta: -

Volume Today

375.91K

Avg: -